

## OPEN PEER REVIEW REPORT 1

**Name of journal:** Neural Regeneration Research

**Manuscript NO:** NRR-D-22-00194

**Title:** Safety, Immunogenicity, Efficacy and Acceptability of COVID-19 vaccination in people with MS: a narrative literature review

**Reviewer's Name:** Elena Giusto

**Reviewer's country:** Italy

### COMMENTS TO AUTHORS

I really enjoyed reading your manuscript "Safety, Immunogenicity, Efficacy and Acceptability of COVID-19 vaccination in people with MS: a narrative literature review".

I think the topic is well explained and easy to follow. I particularly appreciate the statistics, which give strong support to your statements, as well as the plain and fluent English used in the manuscript.

Of course this topic is really hot at the moment, so some overlap with a few recent reviews does exist, which indeed represents the weakest point of this review. Nevertheless, I believe the topic is well covered and provides an interesting recap of the latest studies related to the COVID-19 vaccination of MS patients.

Overall I found only some minor details that need to be adjusted, as follows:

-Line 57: the acronym DMTs is never spelled before

-lines 57-58: I can't see any connection of the sentence starting with "Therefore, patients...protection" with what explained just before. Is this out of place maybe?

-line 66: there is an extra comma after the word "first"

-line 123 and line 174: I think DMD is a mistake? Otherwise, please spell the acronym

-starting from line 147 till the end: in many cases the names of the drugs miss the capital letter

-as a suggestion, I would include some informations about the different strains (e.g. delta, omicron, etc) of the virus, and how these have impacted patients affected by MS